Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Guangxi Center for Disease Control and Prevention | OTHER_GOV |
At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis B and immune response to HB vaccine among Chinese college students to uncover the need on universal mass vaccination or booster immunization only for students with HBV vaccination history against hepatitis B in Chinese college students to inform decision making.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HBV vaccine | Experimental | HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium) | Biological |
|
| Measure | Description | Time Frame |
|---|---|---|
| Anti-HBs immune response in participants negative for HB sAg, anti-HBs and anti-HBc | Anti-HBs was assayed at Month 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Seroprevalence for HBsAg, anti-HBs and anti-HBc in Chinese college students | seroprevalence at baseline | |
| Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc | Anti-HBs immune response at Month 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria for vaccination study:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Guangxi Centers for Disease Control and Prevention | Nanning | Guangxi | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc | Anti-HBs immune response at Month 6 |
| Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc | Anti-HBs immune response at Month 20 |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C075654 | Engerix-B |
| C023768 | halofantrine |
Not provided
Not provided
Not provided